Vinyl Chloride Vinylidene Chloride Copolymer For Pharmaceutical Packaging: Barrier Properties, Formulation Strategies, And Blister Pack Applications

Molecular Composition And Structural Characteristics Of Vinyl Chloride Vinylidene Chloride Copolymer For Pharmaceutical Packaging

The fundamental architecture of vinyl chloride vinylidene chloride copolymer dictates its barrier performance and processability in pharmaceutical packaging applications. The copolymer typically comprises 70–77 wt% vinylidene chloride polymerized with 23–30 wt% vinyl chloride 8, although formulations with vinylidene chloride content ranging from 55% to over 90% have been documented depending on the target application 57. The vinylidene chloride monomer units contribute dense crystalline domains with tightly packed –CH₂–CCl₂– repeating units, which create tortuous diffusion pathways for gas molecules and yield oxygen transmission rates (OTR) as low as 0.05–0.5 cm³/(m²·day·atm) at 23°C and 0% relative humidity for optimized films 10. In contrast, vinyl chloride segments enhance melt flow characteristics and reduce the crystalline melting point from approximately 198°C for PVDC homopolymer to 160–175°C for copolymers containing 3–10 wt% methyl acrylate or vinyl chloride comonomer 7, thereby enabling conventional extrusion and thermoforming processes without extensive thermal degradation.

The crystallinity of these copolymers is a critical parameter governing both barrier properties and mechanical performance. Compositions designed for pharmaceutical blister packs typically exhibit crystallinity in the range of 25–45% as measured by differential scanning calorimetry (DSC) 12, with higher crystallinity correlating to lower gas permeability but reduced flexibility and impact resistance. The relationship between comonomer content and crystalline melting point follows the empirical relation Y ≤ 175 – 3x, where Y is the melting point in °C and x is the methyl acrylate content in wt% 7. This relationship allows formulators to tailor thermal processing windows while maintaining requisite barrier performance. For instance, a copolymer with 5 wt% methyl acrylate would exhibit a melting point ≤160°C, facilitating extrusion at 170–190°C with reduced risk of dehydrochlorination and polymer degradation 7.

Molecular weight distribution also profoundly impacts processing behavior and film integrity. Low molecular weight vinylidene chloride copolymers (weight-average molecular weight Mw = 40,000–60,000 g/mol) exhibit enhanced melt shear stability and reduced die buildup during extrusion, but may require processing aids such as epoxy resins (e.g., epoxidized soybean oil at 1–3 phr) to maintain adequate melt strength and prevent excessive flow 6. The addition of epoxy resins not only improves thermal stability by scavenging liberated HCl during processing but also enhances oxygen barrier performance by reducing free volume within the polymer matrix 6. Conventional stabilizer/plasticizer combinations, such as 2-ethylhexyl diphenyl phosphate (2–6 wt%) paired with epoxy resins, are employed to balance thermal stability, lubrication, and barrier properties 62.

Formulation Strategies And Plasticizer Selection For Enhanced Barrier Performance In Pharmaceutical Packaging

The selection and optimization of plasticizers and polymeric additives are paramount to achieving the requisite balance of flexibility, barrier performance, and thermal stability in vinyl chloride vinylidene chloride copolymer formulations for pharmaceutical packaging. Traditional monomeric plasticizers such as di-isobutyl adipate (2–6 wt%) and ethyl phthalyl ethyl glycolate (2–4 wt%) have been employed to reduce the glass transition temperature (Tg) and improve film flexibility 8, but these low-molecular-weight additives are prone to migration and volatilization, which can compromise long-term barrier stability and lead to embrittlement during storage. To address these limitations, polymeric plasticizers derived from aliphatic polycarboxylic acids and polyhydroxylated aliphatic alcohols—specifically polyesters with molecular weights in the range of 1,000–5,000 g/mol—are increasingly favored 23. These polymeric plasticizers, incorporated at 1–20 wt% relative to the total composition, exhibit negligible migration rates (<0.1 mg/dm² after 10 days at 40°C in 95% ethanol simulant) and maintain plasticization efficacy over extended periods, thereby ensuring consistent mechanical properties and barrier performance throughout the pharmaceutical product's shelf life 2.

Polycaprolactone-based plasticizers represent another advanced approach to formulation optimization. Solid polycaprolactone (PCL) with molecular weights of 10,000–80,000 g/mol, incorporated at 0.5–20 wt%, provides both plasticization and compatibilization functions in vinylidene chloride copolymer matrices 1. PCL enhances the interfacial adhesion between crystalline and amorphous domains, reduces brittleness at low temperatures (down to –20°C), and improves the heat-seal strength of multilayer films by 15–30% compared to formulations using only monomeric plasticizers 1. The hydroxyl and ester functional groups in PCL also contribute to secondary hydrogen bonding with the polar chlorine atoms in the copolymer backbone, which further restricts segmental mobility and reduces gas permeability 1.

Thermal stabilization is critical to prevent dehydrochlorination during melt processing at 170–200°C. Tetrasodium pyrophosphate (0.3–1.75 wt%) functions as an acid scavenger and nucleating agent, promoting uniform crystallization and reducing the formation of voids that could compromise barrier integrity 8. Epoxy resins, particularly epoxidized soybean oil (ESO) and epoxidized linseed oil (ELO) at 1–3 wt%, react with liberated HCl to form stable chlorohydrin species, thereby preventing autocatalytic degradation and extending the thermal processing window 616. The combination of epoxy stabilizers with phosphite antioxidants (e.g., tris(2,4-di-tert-butylphenyl) phosphite at 0.1–0.5 wt%) provides synergistic protection against both thermal and oxidative degradation, ensuring color stability and mechanical integrity in the final pharmaceutical packaging film 16.

Processing Technologies And Extrusion Parameters For Vinyl Chloride Vinylidene Chloride Copolymer Films In Pharmaceutical Packaging

The conversion of vinyl chloride vinylidene chloride copolymer formulations into high-barrier pharmaceutical packaging films requires precise control of extrusion parameters, die design, and post-extrusion orientation processes. Monolayer and multilayer coextrusion techniques are employed depending on the specific performance requirements and cost constraints of the pharmaceutical application. For blister pack base films, a typical three-layer coextruded structure comprises a core layer of vinylidene chloride copolymer (10–25 µm thickness) sandwiched between outer layers of polyvinyl chloride (PVC), polyethylene terephthalate (PET), or ethylene-vinyl acetate (EVA) copolymer (each 25–75 µm) to provide mechanical support, heat-seal functionality, and printability 914. The vinylidene chloride copolymer core layer can be as thin as 0.18 mil (approximately 4.6 µm) when processing aids such as epoxy resins are employed to enhance melt shear stability and reduce die buildup 6.

Extrusion temperatures for vinylidene chloride copolymers are typically maintained in the range of 170–190°C across the barrel zones, with die temperatures of 175–185°C to ensure adequate melt homogeneity while minimizing thermal degradation 616. Screw speeds of 40–80 rpm and specific throughput rates of 15–30 kg/(h·cm die width) are common for cast film extrusion lines producing pharmaceutical-grade barrier films 16. The residence time in the extruder should be minimized to <3 minutes to prevent excessive exposure to elevated temperatures, which can lead to color formation (yellowing) and loss of molecular weight through chain scission 16. Melt filtration through 80–150 mesh screens is essential to remove gels, crosslinked particles, and contaminants that could compromise film clarity and barrier uniformity 16.

Biaxial orientation of vinylidene chloride copolymer films is employed to enhance mechanical strength, reduce thickness variability, and improve barrier performance through alignment of polymer chains and crystalline lamellae. Sequential or simultaneous biaxial stretching at ratios of 3:1 to 5:1 (machine direction:transverse direction) is performed at temperatures 10–20°C above the Tg of the copolymer (typically 60–80°C for plasticized formulations) 9. Orientation increases the tensile strength from 30–50 MPa for cast films to 80–120 MPa for biaxially oriented films, while reducing the oxygen transmission rate by an additional 30–50% due to increased crystallinity and reduced free volume 9. Heat-setting at 120–140°C for 2–5 seconds stabilizes the oriented structure and minimizes shrinkage during subsequent thermoforming operations 9.

Coextrusion with adhesive tie layers is critical when bonding vinylidene chloride copolymer to dissimilar polymers such as plasticized PVC or EVA. A polymeric adhesive consisting of 10–90 parts by weight of vinyl acetate-ethylene copolymer and 90–10 parts by weight of vinyl chloride-vinyl acetate copolymer, with a shear elastic modulus G' > 0.5 × 10³ Pa at 121°C and 10⁻⁴ cycles/second, provides robust interlayer adhesion and prevents delamination during thermoforming and heat-sealing operations 14. Alternative adhesive formulations based on mixtures of polyvinyl acetate and polymethyl methacrylate, with the product of vinyl acetate weight content (%) and dynamic viscosity at 100°C and 1 s⁻¹ (kPa·s) exceeding 1.3 × 10³, have also demonstrated excellent bonding performance in multilayer pharmaceutical packaging structures 15.

Barrier Properties And Permeability Characteristics Of Vinyl Chloride Vinylidene Chloride Copolymer For Pharmaceutical Packaging Applications

The exceptional barrier performance of vinyl chloride vinylidene chloride copolymer films is the primary driver for their adoption in pharmaceutical packaging, particularly for moisture-sensitive and oxygen-sensitive drug formulations. Oxygen transmission rates (OTR) for optimized copolymer films range from 0.05 to 2.0 cm³/(m²·day·atm) at 23°C and 0% relative humidity, depending on copolymer composition, crystallinity, film thickness, and plasticizer content 106. For comparison, uncoated PVC films exhibit OTR values of 50–150 cm³/(m²·day·atm) under identical conditions, representing a 25- to 3000-fold reduction in oxygen permeability when vinylidene chloride copolymer is employed 10. This dramatic improvement is attributed to the high density (1.68–1.72 g/cm³) and crystallinity (25–45%) of the copolymer, which create a tortuous diffusion pathway for gas molecules and minimize free volume available for permeant transport 1210.

Water vapor transmission rate (WVTR) is equally critical for pharmaceutical applications, as many active pharmaceutical ingredients (APIs) undergo hydrolytic degradation or polymorphic transformation in the presence of moisture. Vinylidene chloride copolymer films with 70–77 wt% vinylidene chloride content exhibit WVTR values of 0.5–3.0 g/(m²·day) at 38°C and 90% relative humidity for film thicknesses of 20–40 µm 108. The incorporation of polymeric plasticizers such as aliphatic polyester-based additives at 5–15 wt% can reduce WVTR by an additional 20–40% compared to formulations using monomeric plasticizers, due to the reduced free volume and enhanced interfacial interactions between the plasticizer and copolymer matrix 23. For blister pack applications requiring extended shelf life (24–36 months) in tropical climates (30°C, 75% RH), multilayer structures with a 15–25 µm vinylidene chloride copolymer core layer bonded to 50–75 µm PVC or PET outer layers achieve WVTR values below 0.2 g/(m²·day), ensuring API stability throughout the product lifecycle 10.

The permeability of organic vapors and volatile compounds is also significantly reduced in vinylidene chloride copolymer films. Transmission rates for ethyl acetate, a common solvent used in pharmaceutical processing, are typically <0.01 g/(m²·day) at 23°C for 25 µm films, compared to 5–15 g/(m²·day) for uncoated PVC films 10. This low permeability to organic vapors is particularly important for packaging formulations containing volatile excipients or for preventing the ingress of environmental contaminants such as aldehydes, ketones, and aromatic hydrocarbons that could interact with the API or alter its organoleptic properties 10.

Temperature and relative humidity exert significant effects on barrier performance. OTR increases by a factor of 1.5–2.5 for every 10°C rise in temperature due to increased segmental mobility and free volume expansion 10. Similarly, WVTR increases exponentially with relative humidity, with a 2- to 4-fold increase observed when RH rises from 50% to 90% at constant temperature 10. These dependencies underscore the importance of accelerated stability testing under worst-case storage conditions (e.g., 40°C/75% RH per ICH Q1A guidelines) to validate the adequacy of barrier protection for specific pharmaceutical formulations 10.

Applications Of Vinyl Chloride Vinylidene Chloride Copolymer In Pharmaceutical Blister Pack Manufacturing

Blister packs represent the dominant application for vinyl chloride vinylidene chloride copolymer films in the pharmaceutical industry, accounting for over 60% of global consumption of these materials in healthcare packaging 10. The typical blister pack architecture comprises a thermoformed base with recesses (cavities) to accommodate individual tablets or capsules, surrounded by a shoulder that is heat-sealed to an aluminum foil lidding material (typically 20–25 µm hard-temper aluminum with a heat-seal lacquer coating) 10. The base film is a multilayer structure with a vinylidene chloride copolymer core layer (10–25 µm) providing the primary moisture and oxygen barrier, bonded to outer layers of PVC (50–100 µm) or PET (50–75 µm) that provide mechanical rigidity, thermoformability, and printability 1014.

The thermoforming process for blister pack bases involves heating the multilayer film to 120–160°C (depending on the outer layer polymer) and applying compressed air or vacuum to draw the softened film into a mold cavity, creating the recess geometry 10. The vinylidene chloride copolymer core layer must exhibit sufficient elongation at break (>100% at forming temperature) and resistance to thinning during deep-draw forming (draw ratios up to 1:1.5 for pharmaceutical blisters) to maintain barrier integrity in the formed recess 10. Formulations incorporating polycaprolactone plasticizers at 5–15 wt% demonstrate superior forming performance, with uniform wall thickness distribution (coefficient of variation <15%) and minimal stress-whitening compared to formulations using only monomeric plasticizers 1.

Heat-sealing of the aluminum foil lid to the PVC or PET shoulder of the blister base is performed at temperatures of 160–200°C, dwell times of 0.5–2.0 seconds, and sealing pressures of 0.3–0.8 MPa